Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zydus Lifesciences is a large, commercial-stage pharmaceutical and biotech company with a global footprint across generics, biosimilars, vaccines, and novel new chemical entities. It was the first Indian company to launch a patented NCE (Lipaglyn/saroglitazar) and an adalimumab biosimilar (Exemptia). Dozens of generics are approved in the US, along with both complex generics and biologics. They have a strong ongoing clinical pipeline in NCE, biosimilars, and vaccines, with multiple programs in commercial or late-phase development.[2][4][7][10]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zydus Lifesciences.